Therapeutic Asset Ratings
229 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Surufatinib
Lymphoma
Hutchmed
P1/2
CC
(44)
xnw5004
Lymphoma
Evopoint Biosciences Inc.
P1/2
CC
(44)
Ari-0001
Lymphoma
Baylor College of Medicine
P1
CC
(42)
Enitociclib
Lymphoma
National Cancer Institute (NCI)
P1/2
CC
(42)
Rimiducid
Lymphoma
UNC Lineberger Comprehensive Cancer Center
P1/2
CC
(42)
azd3470
Lymphoma
AstraZeneca
P1/2
CC
(41)
bt02
Lymphoma
Biotroy Therapeutics
P1/2
CC
(41)
cts3497
Lymphoma
CytosinLab Therapeutics Co., Ltd.
P1/2
CC
(41)
eb103
Lymphoma
Estrella Biopharma, Inc.
P1/2
CC
(41)
Eliglustat
Lymphoma
Chinese PLA General Hospital
P1/2
CC
(41)
Enoxaparin
Lymphoma
Medical University of Gdansk
P1/2
CC
(41)
Ex-Vivo Expanded Γδ T Cell Infusion
Lymphoma
Chinese PLA General Hospital
P1/2
CC
(41)
Fosdesdenosine Sipalabenamide
Lymphoma
NuCana plc
P1/2
CC
(41)
Gecacitinib
Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
P1/2
CC
(41)
hlx301
Lymphoma
Shanghai Henlius Biotech
P1/2
CC
(41)
IM19 CAR-T cells
Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
P1/2
CC
(41)
Neratinib
Lymphoma
Memorial Sloan Kettering Cancer Center
P1/2
CC
(41)
ose2101
Lymphoma
OSE Immunotherapeutics
P1/2
CC
(41)
OSE-279
Lymphoma
OSE Immunotherapeutics
P1/2
CC
(41)
Part A: Ose-279
Lymphoma
OSE Immunotherapeutics
P1/2
CC
(41)
Penpulimab
Lymphoma
WEI XU
P1/2
CC
(41)
Pirtobrutinib
Lymphoma
Inhye Ahn
P1/2
CC
(41)
Ponatinib
Lymphoma
Incyte Biosciences International Sàrl
P1/2
CC
(41)
Repotrectinib
Lymphoma
Turning Point Therapeutics, Inc.
P1/2
CC
(41)
Scri-Car22V2
Lymphoma
Seattle Children's Hospital
P1/2
CC
(41)
Showing 151 to 175 of 229 assets
Previous
Page 7 of 10
Next
